# Acute Myeloid Leukemia:  Developing Drugs and Biological Products for Treatment: Draft Guidance for Industry - FDA Guidance Document

Source: https://www.keypedia.com/guidances/guidance-document/acute-myeloid-leukemia-developing-drugs-and-biological-products-for-treatment-draft-guidance-for-industry/8143a606-18fc-488c-b3ab-4c23bdcd999a

> FDA guidance document: Acute Myeloid Leukemia:  Developing Drugs and Biological Products for Treatment: Draft Guidance for Industry. Issue date: August 17, 2020. Get complete insights and analysis.

---

## Details

- Title: Acute Myeloid Leukemia:  Developing Drugs and Biological Products for Treatment: Draft Guidance for Industry
- Communication Type: Guidance Document
- Product Type: biologics
- Office Name: Office of the Commissioner
- Office URL: /offices/office-of-the-commissioner/79483979-9582-427f-ac3d-46c715811424
- Issue Date: 2020-08-17
- Comment Close Date: 2020-10-13
- Last Changed: 2020-08-17
- Docket Number: <a href="https://www.regulations.gov/docket/FDA-2020-D-1298">FDA-2020-D-1298</a>

## Related Documents

- [Prevention and Treatment of Chemotherapy-Induced Peripheral Neuropathy: Developing Drug and Biological Products in Oncology](https://www.keypedia.com/guidances/guidance-document/prevention-and-treatment-of-chemotherapy-induced-peripheral-neuropathy-developing-drug-and-biological-products-in-oncology/21c15304-ad79-4fb0-8609-1712f3c9952b)
- [Real-World Evidence: Considerations Regarding Non-Interventional Studies for Drug and Biological Products](https://www.keypedia.com/guidances/guidance-document/real-world-evidence-considerations-regarding-non-interventional-studies-for-drug-and-biological-products/48325e39-b445-4a53-8cc0-7483dcf3e352)
- [Setting Endotoxin Limits During Development of Investigational Oncology Drugs and Biological Products Guidance for Industry: Draft Guidance for Industry](https://www.keypedia.com/guidances/guidance-document/setting-endotoxin-limits-during-development-of-investigational-oncology-drugs-and-biological-products-guidance-for-industry-draft-guidance-for-industry/ef751a3a-e9d6-4489-b86d-73f2411682c1)